Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.39M P/E - EPS this Y 7.00% Ern Qtrly Grth -
Income -22.27M Forward P/E -0.63 EPS next Y 30.20% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -7.00%
Dividend N/A Price/Book 0.22 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.00 Quick Ratio 2.71 Shares Outstanding 1.35M 52W Low Chg 76.00%
Insider Own 0.58% ROA -24.98% Shares Float 1M Beta 1.39
Inst Own 2.44% ROE -59.06% Shares Shorted/Prior 90.98K/3.99K Price 0.69
Gross Margin - Profit Margin - Avg. Volume 749,319 Target Price 100.00
Oper. Margin - Earnings Date Nov 11 Volume 127,579 Change 5.68%
About Theriva Biologics, Inc.

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Theriva Biologics, Inc. News
12/05/24 Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
11/12/24 Theriva Biologics: Q3 Earnings Snapshot
10/31/24 Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
10/16/24 Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
10/03/24 Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients
10/03/24 Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
09/26/24 Theriva Biologics Announces Pricing of $2.5 Million Public Offering
09/23/24 Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
09/16/24 Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program
08/26/24 Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested
08/16/24 Theriva Biologics Announces Reverse Stock Split
08/13/24 Theriva Biologics: Q2 Earnings Snapshot
08/13/24 Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results
07/31/24 Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
05/23/24 Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
05/14/24 Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
05/07/24 Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
07:15 AM Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04/23/24 Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
04/22/24 Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jun 07 Buy 0.6931 14,000 9,703 250,000 06/08/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jun 06 Buy 0.6328 26,000 16,453 236,000 06/07/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Feb 10 Buy 1.043 25,000 26,075 210,000 02/13/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Feb 02 Buy 0.9405 25,000 23,512 185,000 02/03/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jan 25 Buy 0.873 25,000 21,825 160,000 01/26/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Jan 20 Buy 0.7482 25,000 18,705 135,000 01/23/23
SHALLCROSS STEVEN A CEO and CFO CEO and CFO Dec 29 Buy 0.437 100,000 43,700 110,000 01/03/23